Partial
Partially Aligned
Patient Risk:
Low
Summary
Some statements align with the provided AJOVY label excerpts (indication, adult/pediatric preventive use, and subcutaneous administration). However, multiple mechanistic/biologic claims and specific product/manufacturer assertions are not supported by the supplied label text, and one approval-timing detail is not supportable from the provided sections.
Category Scores
Accurate Statements
Fremanezumab is a calcitonin gene-related peptide (CGRP) ligand monoclonal antibody.
Supported by the provided drug information: "fremanezumab-vfrm (AJOVY) (calcitonin gene-related peptide [CGRP] ligand monoclonal antibody)".
Fremanezumab is used to prevent migraine headaches.
Supported by Section 1: AJOVY indicated for preventive treatment of migraine in adults (and episodic migraine in pediatric patients 6–17 years).
Fremanezumab is administered via subcutaneous injection.
Supported by Section 2.1 and Section 2.2: recommended dosage is administered by subcutaneous injection; AJOVY is for subcutaneous use only.
Unsupported Statements
The generic name for Ajovy is fremanezumab.
Not supported or contradicted by the provided label excerpts. The prompt provides "fremanezumab-vfrm (AJOVY)" but does not explicitly state the generic name mapping as 'fremanezumab' alone.
Fremanezumab is a CGRP inhibitor.
No CGRP-inhibitor phrasing is present in the provided label excerpts.
Fremanezumab is a monoclonal antibody that targets the CGRP pathway.
Mechanistic 'CGRP pathway' targeting language is not present in the provided label excerpts.
CGRP is released during migraine attacks and contributes to pain and inflammation.
No such mechanistic background is provided in the supplied label excerpts.
By blocking CGRP, fremanezumab is thought to reduce the frequency of migraine headaches.
The provided excerpts do not include this mechanistic rationale.
Ajovy received U.S. Food and Drug Administration (FDA) approval in September 2018 for the preventive treatment of migraine in adults.
FDA approval month/year is not provided in the supplied label excerpts.
Fremanezumab targets the CGRP ligand.
Not explicitly supported by the provided label excerpt text, though the prompt's drug information states 'CGRP ligand monoclonal antibody.' This specific 'targets the CGRP ligand' wording is not shown in the provided label sections.
Ajovy is manufactured by Teva Pharmaceutical Industries.
Manufacturer information is not included in the supplied label excerpts.
Contradictions
Important Omissions
For pediatric use, the claim did not mention the label-specific restriction of pediatric patients 6–17 years who weigh 45 kg or more, and that AJOVY is not approved for pediatric patients weighing less than 45 kg.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported mechanistic statements and manufacturer/approval-date details do not directly change dosing or labeled safety requirements based on the provided excerpts. However, omission of the pediatric weight/age approval boundary could matter if the claims were intended for pediatric populations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims (mechanism, FDA approval timing, manufacturer) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to what is explicitly supported by the supplied label sections (Indications: preventive migraine in adults and episodic migraine in pediatric 6–17 years who weigh ≥45 kg; Administration: subcutaneous use; Dosing options in adults). Avoid approval-date, manufacturer, and detailed mechanistic CGRP-pathway wording unless present in the label text you are auditing.